You are here: Industry Insights > NMPA

News List

China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL prnasia
January 14, 2021
Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted approval for a pivotal seamless Phase 1/2 clinical ...
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer prnasia
January 12, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced with Eli Lilly and ...
Innovent Announces NMPA Approves BYVASDA for Adult Recurrent Glioblastoma americanpharmaceuticalreview
January 08, 2021
Innovent Biologics has announced BYVASDA® (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the National Medical Products Administration (NMPA) of ...
Innocare Gets Approval from NMPA for Orelabrutinib contractpharma
January 08, 2021
Innocare has received approval by the National Medical Products Administration of China (NMPA) for Orelabrutinib, an orally available potent BTK inhibitor that irreversibly binds to BTK to induce downstream kinase inactivation and cell death.
China grants conditional market approval for Sinopharm CNBG's COVID-19 vaccine worldpharmanews
January 06, 2021
The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, Chinese equivalent of FDA, according to a press conference of the ...
Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma prnasia
December 28, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces that BYVASDA® ...
Innovent Announces NMPA Granted New Indication Approvals for SULINNO® (Adalimumab Injection) for the Treatment of Pediatric Plaque Psoriasis and Non-infectious Uveitis prnasia
December 23, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces that SULINNO® ...
Henlius Adalimumab Biosimilar Approved by NMPA prnasia
December 09, 2020
Shanghai Henlius Biotech, Inc. announced that the adalimumab biosimilar HLX03, developed and manufactured by the Company independently, has been approved by the National Medical Products Administration (NMPA) for the treatment of rheumatoid arthritis ...
Regent Pacific's Strategic Partner Receives Approval from NMPA to Submit IND Application prnasia
December 03, 2020
Regent Pacific Group Limited, a specialist healthcare, wellness and life sciences investment group is pleased to announce that Wanbang Pharmaceutical Marketing and Distribution Co., Ltd., a wholly controlled company of Shanghai Fosun Pharma ...
CStone Pharmaceuticals Announces China's NMPA has Accepted its New Drug Application for anti-PD-L1 Monoclonal Antibody Sugemalimab in First-Line Advanced NSCLC prnasia
November 12, 2020
CStone Pharmaceuticals, a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, announced that China's National Medical Products Administration (NMPA) has accepted ..

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page